Loading…
Dianthus Therapeutics, Inc. is projected to rise to $124.62 by 2027, a +44% move from its current price of $86.67. DNTH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $84.92 | $86.72 | $88.56 | +0.06% |
| May 30 | $84.23 | $86.77 | $89.38 | +0.11% |
| May 31 | $83.71 | $86.81 | $90.03 | +0.17% |
| Jun 1 | $83.29 | $86.86 | $90.59 | +0.22% |
| Jun 2 | $82.92 | $86.91 | $91.09 | +0.28% |
| Jun 3 | $82.60 | $86.96 | $91.55 | +0.33% |
| Jun 4 | $82.30 | $87.01 | $91.98 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $82.30 | $87.01 | $91.98 | +0.39% |
| Week 2 | $80.75 | $87.35 | $94.48 | +0.78% |
| Week 3 | $79.64 | $87.68 | $96.54 | +1.17% |
| Week 4 | $78.77 | $88.03 | $98.37 | +1.56% |
| Week 5 | $78.04 | $88.37 | $100.06 | +1.96% |
| Week 6 | $77.42 | $88.71 | $101.64 | +2.35% |
| Week 7 | $76.88 | $89.06 | $103.16 | +2.75% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. It is categorized in Healthcare.
DNTH is a healthcare company trading under the symbol DNTH. The current price is $86.48 and the market cap is $4.73B, with a rank of 1378.
The forecast implies the 2026 average price near the current level at $86.48 with a neutral sentiment and ROI 0. The series then shows bullish momentum with rising averages and upside into 2027–2050. Key long-horizon points include 2030 with an average of $231.43 and max $324.96 (ROI 167.6, sentiment BULLISH), 2040 with an average of $684.74 and max $1,091.92 (ROI 691.8, sentiment BULLISH), and 2050 with an average of $1,754.79 and max $3,025.40 (ROI 1929.1, sentiment BULLISH).
A major floor 49.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 10.5% above — a clean break opens room to run.
A major ceiling 16.4% above — clearing it would confirm fresh momentum.
Key DNTH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNTH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $87.66 | Sell | $86.94 | Sell |
| MA 10 | $86.48 | Buy | $86.90 | Sell |
| MA 20 | $86.95 | Sell | $86.93 | Sell |
| MA 50 | $86.37 | Buy | $82.90 | Buy |
| MA 100 | $69.71 | Buy | $72.76 | Buy |
| MA 200 | $52.60 | Buy | $58.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.35 | Neutral |
| Stoch RSI (14) | 48.35 | Neutral |
| CCI (20) | -12.37 | Neutral |
| Williams %R (14) | -49.09 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -0.05 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 50.91 | Neutral |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -0.83 | Sell |
| Ultimate (7,14,28) | 47.62 | Neutral |
| Momentum (10) | 0.52 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 87.64 | Sell |
| ADX (14) | 11.67 | Neutral |
| ATR (14) | 1.53 | Info |
The 30-day technical picture is bullish. RSI14 is 50 and the moving averages show SMA50 at $86.01 and SMA200 at $51.93. The 30-day range runs from $74.65 to $100.18, with a support level at $83.50 and resistance at $95.76. Annualized volatility is 40%.
Overall, the near-term setup suggests modest upside potential around the current price, with defined support and resistance levels to monitor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $36.20 | $86.67 | $122.81 | 0% | Neutral | |
| $101.05 | $124.62 | $161.41 | +44% | Bullish | |
| $131.66 | $165.70 | $220.80 | +91% | Bullish | |
| $152.32 | $194.98 | $265.75 | +125% | Bullish | |
| $178.03 | $231.32 | $321.40 | +167% | Bullish | |
| $205.09 | $270.12 | $381.71 | +212% | Bullish | |
| $211.65 | $282.30 | $405.07 | +226% | Bullish | |
| $240.69 | $324.84 | $472.64 | +275% | Bullish | |
| $281.71 | $384.47 | $566.61 | +344% | Bullish | |
| $329.13 | $453.99 | $677.13 | +424% | Bullish | |
| $480.50 | $695.25 | $1,090.76 | +702% | Bullish | |
| $1,124.12 | $1,762.50 | $2,979.95 | +19.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $36.20 | $86.67 | $101.79 | +0.00% |
| June 2026 | $77.06 | $90.05 | $107.39 | +3.90% |
| July 2026 | $77.52 | $91.16 | $109.86 | +1.23% |
| August 2026 | $76.27 | $90.16 | $109.52 | -1.11% |
| September 2026 | $77.71 | $92.23 | $112.78 | +2.30% |
| October 2026 | $80.67 | $96.11 | $118.23 | +4.21% |
| November 2026 | $81.34 | $97.24 | $120.23 | +1.17% |
| December 2026 | $82.41 | $98.83 | $122.81 | +1.64% |
Click any year to see its month-by-month DNTH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Dianthus Therapeutics, Inc.'s 2026 outlook centres on $86.67, within a $36.20 to $122.81 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DNTH could reach as high as $161.41, with a base case around $124.62 and support toward $101.05 — roughly +44% from $86.67. Momentum favours further upside here.
Expect DNTH to range from $131.66 to $220.80 through 2028. The $165.70 average target implies a +91% move from current prices. That is up +33% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The DNTH price prediction for 2029 points to an average of $194.98 (low $152.32, high $265.75) — a potential gain of +125% on today's $86.67. Momentum favours further upside here.
In 2030, DNTH is projected to trade between $178.03 and $321.40, averaging $231.32 — a potential gain of +167% from today's $86.67. That is up +19% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Dianthus Therapeutics, Inc.'s 2031 outlook centres on $270.12, within a $205.09 to $381.71 range. That is up +17% on the projected 2030 average. That marks a +212% change versus current levels. Momentum favours further upside here.
By 2032, DNTH could reach as high as $405.07, with a base case around $282.30 and support toward $211.65 — roughly +226% from $86.67. Buyers look set to stay in control over this stretch.
Expect DNTH to range from $240.69 to $472.64 through 2033. The $324.84 average target implies a +275% move from current prices. That is up +15% on the projected 2032 average. Momentum favours further upside here.
The DNTH price prediction for 2034 points to an average of $384.47 (low $281.71, high $566.61) — a potential gain of +344% on today's $86.67. Buyers look set to stay in control over this stretch.
In 2035, DNTH is projected to trade between $329.13 and $677.13, averaging $453.99 — a potential gain of +424% from today's $86.67. That is up +18% on the projected 2034 average. Momentum favours further upside here.
Dianthus Therapeutics, Inc.'s 2040 outlook centres on $695.25, within a $480.50 to $1,090.76 range. That is up +53% on the projected 2035 average. That marks a +702% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DNTH could reach as high as $2,979.95, with a base case around $1,762.50 and support toward $1,124.12 — roughly +19.3x from $86.67. Momentum favours further upside here.
Investing $1,000 in DNTH today (≈ 11.538018 DNTH) could be worth
$20,335.8
+$19,335.8 (+1934%) by 2050 · US Dollar
Based on the average projected DNTH price of $1,762.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNTHwould be worth at today's price.
$1,000 invested in DNTH on May 27, 2025 (≈ 55.772447 DNTH) would be worth
$4,833.8
+$3,833.8 (+383.4%) today · 4.83× · US Dollar
Based on a DNTH entry price of $17.93 vs. today's $86.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $88.72 | $976.89 | -2.3% |
| 1 month ago | $87.16 | $994.38 | -0.6% |
| 3 months ago | $53.11 | $1,631.9 | +63.2% |
| 6 months ago | $43.98 | $1,970.67 | +97.1% |
| 1 year ago | $17.93 | $4,833.8 | +383.4% |
| All time (5.0y) ago | $206.56 | $419.59 | -58.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNTH forecast.
Our base-case forecast reaches $170.00 around 2029.
Implied market cap at $170.00: $9.29B
The multi-year forecast shows substantial upside beyond 2026. For 2030, the expected range is min $176.62, avg $231.43, max $324.96 with ROI of 167.6 and a bullish sentiment. In 2040, the forecast moves to min $465.52, avg $684.74, max $1,091.92 with ROI of 691.8 and a bullish sentiment.
By 2050, the range is min $1,093.61, avg $1,754.79, max $3,025.40 with ROI of 1929.1 and a bullish sentiment.
These projections imply strong upside potential over the long term, but as with any forecast, they are estimates and not guarantees. Investors should consider the inherent uncertainty embedded in long-range price projections.
Tap a question to reveal the answer.
2030 avg $231.43; min $176.62; max $324.96; ROI 167.6; sentiment BULLISH.
Forecasts show 2026 avg $86.48; ROI 0; sentiment NEUTRAL, followed by 2027 avg $124.61; ROI 44.1; sentiment BULLISH, and continued bullish outlook through 2050. These are estimates, not guarantees.
2033 max $476.20; min $236.78; avg $323.14; ROI 273.6; sentiment BULLISH.
Sentiment BULLISH. RSI14 is 50; SMA50 is $86.01; SMA200 is $51.93. 30-day range is $74.65 to $100.18; support $83.50; resistance $95.76; annualized volatility 40%.
2040 avg $684.74; min $465.52; max $1,091.92; ROI 691.8; sentiment BULLISH.
Dianthus Therapeutics, Inc. Community Discussion
0Share your Dianthus Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.